Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Once-weekly semaglutide 2.0 mg plus reduced insulin glargine vs titrated insulin glargine in type 2 diabetes with overweight
2021-004392-13Phase 3Active
- Sponsor
- Novo Nordisk
- Start
- Dec 2021
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 3, randomised trial of semaglutide in type 2 diabetes mellitus (T2DM) and Overweight (2 arms), sponsored by Novo Nordisk. Primary endpoint: Change in HbA1c. Started Dec 2021; status: active.
02
Drugs
03
Conditions
type 2 diabetes mellitus (T2DM)Overweight
Beyond the preview
Go deeper on 2021-004392-13.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-004392-13.